Home
About Us
About Us
Our Team
News & Press
Why Ultra-Rare Diseases
Our Model
Therapy Tracker
Contact
Select Page
MVX-220
Back to Therapy Pipeline
Submitting Organization:
Foundation for Angelman Syndrome Therapeutics (FAST)
Treatment Modality:
Gene Therapy
Development Stage:
Phase I/II Clinical Trial